Federal Mandate Slashes Insulin Costs for Millions of Medicare Part D Beneficiaries Following 2022 Inflation Reduction Act

Johns Hopkins study finds Inflation Reduction Act's $35 insulin cap reduced average Medicare costs by over 50%, though some pro-rating gaps remain.

By: AXL Media

Published: Mar 20, 2026, 11:31 AM EDT

Source: Information for this report was sourced from Johns Hopkins Bloomberg School of Public Health

The Economic Impact of the Inflation Reduction Act on Diabetes Care

The implementation of the Inflation Reduction Act of 2022 has triggered a significant shift in the affordability of life saving medication for American seniors. According to a new analysis from the Johns Hopkins Bloomberg School of Public Health, the federal mandate capping out-of-pocket insulin costs at $35 for a 30 day supply has effectively reined in prices across the nation. This study, published in JAMA, represents the first comprehensive look at how the January 1, 2023, mandate has impacted the 3.8 million Medicare Part D beneficiaries who rely on insulin to manage Type 1 and Type 2 diabetes.

Statistical Evidence of Improved Access and Affordability

The researchers analyzed five years of Medicare claims data, revealing a dramatic improvement in cost distribution for patients. In 2019, fewer than half of Medicare insulin users paid $35 or less for their monthly supply. By 2023, that figure surged to 75%, indicating that the vast majority of beneficiaries are now seeing the direct benefits of the federal price ceiling. Lead author Michael Fang, PhD, noted that insulin costs for this demographic are currently at historically low levels, providing compelling evidence that the policy has achieved its primary goal of enhancing medication access.

Widespread Geographic Cost Reductions

The downward trend in insulin pricing was not isolated to specific regions but was observed in every U.S. state between 2019 and 2023. The mean out-of-pocket cost for a standard 30 day equivalent supply dropped from $50.87 to $21.98 over the study period. While the mandate ensures a $35 maximum, many beneficiaries are paying even less depending on their specific plan and state regulations. For example, average costs in 2023 ranged from a low of $10.36 in Washington, D.C., to $31.09 in Minnesota, reflecting a broad success in lowering the financial barrier to diabetes treatment nationwide.